Treatment of Osteomyelitis in Clinically Stable Children with AHO and a Substantial Abscess (>2 cm)
This protocol addresses children with acute haematogenous osteomyelitis (AHO) who remain clinically stable but have a documented substantial abscess greater than 2 cm. Clinical stability alone does not determine the management approach — the size of the abscess is a critical decision point.
In this specific sub-group, medical therapy alone is considered insufficient. Current evidence supports debridement over an antimicrobial-only strategy (conditional recommendation, very low certainty of evidence).
Management combines surgical debridement of the abscess with systemic empiric antimicrobial therapy directed against S. aureus. The choice of antimicrobial agent is shaped by regional CA-MRSA prevalence thresholds, and the protocol includes defined criteria for transitioning from intravenous to oral therapy to complete the course. The complete algorithm — including agent selection, sequencing, and oral step-down — is available in the full protocol.
- Resolution of fever within 3 to 5 days of initiating therapy
- Decline in serum CRP of at least 50% within 4 days of therapy
References
DOI: 10.1093/jpids/piab027
- In a child with AHO who is clinically stable but is documented to have a substantial abscess (greater than 2 cm), we suggest debridement rather than treating with medical therapy alone (conditional recommendation and very low certainty of evidence).
- In children with suspected AHO, we recommend using empiric antimicrobial therapy active against S. aureus (strong recommendation, and moderate certainty of evidence).
- Regarding the choice of anti-staphylococcal therapies, in regions where the prevalence of CA-MRSA causing pediatric AHO is low, cefazolin or oxacillin/nafcillin is preferred for empiric therapy of presumed MSSA infection based on greater safety and tolerability, compared with vancomycin or clindamycin, and greater efficacy compared with vancomycin; for regions with CA-MRSA prevalence 10% to 20% or greater, clindamycin or vancomycin is preferred.
- Excellent outcomes with the transition to oral therapy with high-dose cephalexin or clindamycin are well documented.
- Fever, when present, usually resolves within 3 to 5 days in uncomplicated courses.
- In a series of 26 children with AHO, 92% experienced a decline in CRP of at least 50% within 4 days of therapy.